Literature DB >> 6250995

Relative risk factors in the treatment of juvenile nasopharyngeal angiofibroma.

B J Cummings.   

Abstract

The potentially fatal complications associated with surgery and radiation therapy in the management of juvenile nasopharyngeal angiofibroma (JNA) are analyzed. Quantitative risk factors established from review of the literature suggest a risk of potentially fatal complications of 1 in 3,000 from general anesthesia, 1 in 1,600 from arteriography, 1 in 160 from blood transfusion, and 1 in 500 from the surgical procedure itself. The total of these risks is comparable to the 1% lifetime risk of developing a radiation-induced tumor after radiation therapy. The time pattern of these complications differs in that fatal radiation-induced complications are delayed, whereas the risks associated with surgery, general anesthesia, and blood transfusion are more immediate. However, it is suggested that treatment-related risks of fatal complications are of a similar order of magnitude for surgery and for radiation therapy in the management of JNA.

Entities:  

Mesh:

Year:  1980        PMID: 6250995     DOI: 10.1002/hed.2890030106

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  4 in total

1.  Laser-assisted bypass of the internal carotid artery prior to treatment of an extensive angiofibroma.

Authors:  K Graamans; C A Tulleken
Journal:  Skull Base Surg       Date:  1998

2.  Recurrent juvenile nasopharyngeal angiofibroma treated with gamma knife surgery.

Authors:  Chul-Kee Park; Dong Gyu Kim; Sun Ha Paek; Hyun-Tai Chung; Hee-Won Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 3.  The biology and pathology of selected skull base tumors.

Authors:  L Barnes; S B Kapadia
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Review of skull base surgery approaches: with special reference to pediatric patients.

Authors:  J D Kennedy; S J Haines
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.